CPTS Conceptus, Inc. featured news, full reports, and detailed charts
Conceptus, Inc. (CPTS) Wrap Up:
We develop, manufacture and market the Essure® permanent birth control system, an innovative and proprietary medical device for women that was approved for marketing in the United States in November 2002 by the United States Food and Drug Administration (or FDA). The Essure system uses a soft and flexible micro-insert that is delivered into a woman's fallopian tubes to provide permanent birth control by causing a benign tissue in-growth that blocks the fallopian tubes. A successfully placed Essure micro-insert and the subsequent tissue growth prohibits the egg from traveling through the fallopian tubes and therefore prevents fertilization. The Premarket Approval, or PMA, supplement filed in January 2005 and approved in July 2005 by the FDA supports an extension of the effectiveness rate of the Essure system to 99.80% after four years and 99. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f03%2f14%2f0001047469-08-002756.html#FIS_BUSINESS"Conceptus, Inc. (CPTS:NASDAQ)
Snapshot of Conceptus, Inc. (CPTS)
|
OPEN
$16.84
|
PREVIOUS CLOSE
$16.90
|
|
|
DAY HIGH
$17.33
|
DAY LOW
$16.84
|
|
|
52 WEEK HIGH
10/22/09 - $20.00
|
52 WEEK LOW
03/9/09 - $10.26
|
|
|
MARKET CAP
528.5M
|
AVERAGE VOLUME 3 mo
341.7K
|
|
|
DILUTED EPS TTM
$0.20
|
SHARES OUTSTANDING
30.7M
|
|
|
CPTS Does Not Pay Dividends
|
P/E TTM
87.4x
|
|
| K = Thousands M = Millions B = Billions | ||
related news
The maker of the minimally invasive Essure alternative to tubal ligation for preventing pregnancy is gaining traction
CPTS Top Compensated Officers
Executives, Board Directors
Key developments for Conceptus, Inc. (CPTS)
Conceptus, Inc. - Conference Presentation Calls
Conceptus Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2009. Net sales for the third quarter of 2009 were $34.2 million, an increase of 29% compared with net sales of $26.6 million for the third quarter of 2008. These results exceeded the Companys net sales guidance of $32.0 million to $33.5 million issued on July 22, 2009. Net income for the third quarter of 2009 was $6.2 million, or $0.20 per fully diluted share, compared with net income for the same period of 2008 of $2.0 million, or $0.06 per fully diluted share. These results were also better than the Companys net income guidance of $0.06 to $0.07 per fully diluted share issued in July 2009. The Company recorded a benefit in the third quarter of 2009 of $0.05 per fully diluted share due to the release of the Companys royalty obligations under the 2003 Settlement Agreement between Ovion and Conceptus following the $23.7 million cash acquisition of the Ovion patents. Non-GAAP net income for the third quarter of 2009 was $9.2 million, or $0.29 per fully diluted share, compared with non-GAAP net income for the prior year third quarter of $4.7 million, or $0.15 per fully diluted share. The company reported operating income of $7.997 million and income before provision for income taxes of $6.382 million compared to the operating income of $3.581 million and income before provision for income taxes of $2.130 million for the same period a year ago. The company announced cash flow from operations of $10.5 million. For the nine months ended September 30, 2009, Conceptus reported net sales of $94.4 million, up 29%, compared with net sales of $73.5 million for the first nine months of 2008. Net income for the first nine months of 2009 was $1.3 million, or $0.04 per fully diluted share, compared with a net loss of $7.8 million, or $0.26 per share, for the first nine months of 2008. The company reported operating income of $6.448 million and income before provision for income taxes of $1.714 million compared to the operating loss of $4.011 million and loss before provision for income taxes of $7.562 million for the same period a year ago. The company reported non-GAAP net income of $9.921 million or $0.32 per diluted share compared to the non-GAAP net income of $458,000 or $0.01 per diluted share for the same period a year ago. The Company also introduced financial guidance for the fourth quarter of 2009, and narrowed 2009 net sales and increased net income guidance ranges, as follows: The Company expects net sales for the fourth quarter of 2009 to be $37.5 million to $38.0 million, with a full year range of $131.9 million to $132.4 million. This compares with previous full year net sales guidance in the range of $130.0 million to $133.0 million. The company anticipates fourth quarter GAAP earnings per fully diluted share to be in the range of $0.19 to $0.21 and non-GAAP earnings per fully diluted share to be in the range of $0.31 to $0.33. Full year GAAP earnings per fully diluted share is expected to be in the range of $0.23 to $0.25, which exceeds the previous GAAP earnings guidance range of $0.13 to $0.22 per fully diluted share. Full year non-GAAP earnings guidance is now $0.62 to $0.64 per fully diluted share, above the previous guidance of $0.49 to $0.58 per fully diluted share.
Conceptus, Inc. expected to Report Fiscal Year 2009 Results on February 15, 2010. This event was calculated by Capital IQ (Created on October 21, 2009).
CPTS Competitors
| Company | Last | Change |
| Hologic Inc | $14.39 USD | -0.68 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | CPTS | Industry Range |
| Price/Earnings | 57.4x |
|
| Price/Sales | 4.2x |
|
| Price/Book | 9.9x |
|
| Price/Cash Flow | 57.1x |
|
| TEV/Sales | 2.6x |
|
|
CPTS |
||
CPTS transactions
| Type Date |
Target |
|
Merger/Acquisition
September 30, 2009 |
Ovion, Inc. |
More Recent News About Conceptus, Inc.
More news for CPTS
Conceptus Earnings Call scheduled for 4:30 pm ET today
Call DetailsConceptus Earnings Conference Call (Q3 2009)Wed, Oct 21, 2009, 4:30 pm EasternAbout Conceptus (NasdaqGM:CPTS)Conceptus, Inc. designs, develops, and markets minimally invasive devices for reproductive medical applications in the United States. The company offers Essure, a permanent birth control system for women. The Essure system uses a micro-insert that is delivered into a woman's fallopian tubes to provide permanent birth control by causing a benign tissue in-growth that blocks the fallopian tubes. The company distributes its products through direct sales force and distributor networks, as well as media, including television, radio, direct mail, and print to gynecologists and general practitioners. Conceptus, Inc. was founded in 1992 and is headquartered in Mountain View, California.More Info:Quote |Chart |News |Profile |Reports |Research |SEC |Msgs |Insider | Analyst Ratings...Click here to read the whole Article (external link)
CONCEPTUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial Statements a
Show all filings for CONCEPTUS INC | Request a Trial to NEW EDGAR Online Pro Form 8-K for CONCEPTUS INC 21-Oct-2009Results of Operations and Financial Condition, Other Events, Financial Statements a Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provide...Click here to read the whole Article (external link)
Essure® to Be Highlighted at 18th Annual Congress of the European Society for Gynaecological Endoscopy
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Conceptus, Inc. (Nasdaq: CPTS - News), Essure®Essure® th Annual Congress of the European Society for Gynaecological Endoscopy (ESGE) in Florence, Italy from October 28-31, 2009. Essure® Essure® Permanent Birth Control: Worldwide Experience 2000 to 2009.†Essure®, zero pregnancies in clinical studies and the 94.6% bilateral placement rate of the device.Essure® Essure® device is the most effective, safe and convenient method of female sterilization available, and should be offered to all women seeking permanent contraception.â€Essure® procedure is the only procedure on the market to have zero pregnancies in clinical trials and more than 100,000 women throughout Europe relying on the device.About the Essure® ProcedureEssure® procedure is a permanent birth control method that can be done in the comfort of a physician’s office in about 13 minutes (average hysteroscopic procedure time) without hormones, cutting, burning or the risks associated with general anesthesia or tubal ligation. Small, flexible micro-inserts are placed in the woman’s fallopian tubes through the cervix without incisions. Over the next three months, the body forms a ...Click here to read the whole Article (external link)
New Star Analyst Rankings for Conceptus, Inc.
Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Copyright © 1999-2003, StarMine Corp. All rights reserved.StarMine Corp. derives analyst ratings from estimate and recommendation data supplied by Thomson Financial.Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). International historical chart data, daily updates, fund summary, fund performance, dividend data and...Click here to read the whole Article (external link)
Conceptus downgraded by Sun Trust Rbsn Humphrey
Quotes for CPTS - Yahoo! Finance #screen,#masthead{text-align:center;margin:0;width:752px;} #screen.xpand,#masthead.xpand{width:100%;} #screen.xpand #yfncsubtit{width:100%;} #masthead{padding-bottom:12px;} #leftcol,#rightcol{margin:0;} #leftcol{width:155px;float:left;} #rightcol{width:585px;} #content{width:752px;} #footer {clear:both;} /*/*/ body{text-align:center;} #screen{text-align:left;min-width:700px;width:62.5em;width:expression( document.all.footer ? (document.all.footer.offsetWidth>1000) ? '980'+'px' : document.all.footer.offsetWidth :'62.5'+'em') ;margin:auto;border:1px solid #FFF;} #screen.xpand{width:100%; text-align:center} #portfolio{margin:10px auto;} #hdrads{margin:10px auto 0 auto;} #masthead,#leftcol,#rightcol{margin:0;} #masthead{width:100%;} #leftcol{float:left;width:18%;} #rightcol{float:right;width:80%;} #content{width:100%;} #footer{clear:both;text-align:center;padding:10px 0;width:60em;margin:auto;border:0px solid #FFF;} #leftNavTable,#yfncmh,#yfncmkttme,#yfncduplgnwrn,#yfncpsnlbar,#yfnctitbar,#y fncsubtit,#yfncbrobtn,#yfncsumtab, .yfnc_systitlelinea1,.yfnc_systitlelineb1,.yfnc_modtitlew1{ width:100%;} #yfncmh{width:100%;} .yfncsumdatagrid{background:#DCDCDC;width:100%;} .yfnc_modtitlew2{width:49%;} /**/ .yfncnhl{color:#666;margin-bottom:10px;} .yfncnhl .yfncnhlbl{color:#000;width:1.6em;text-align:center;} .yfncnhl .yfncnhltt{color:#000;width:50px;padding-top:2px;} .yfncnhltt { position: relative; } .yfncnhltt a { position: relative; display: block; /* opera */ width: 42px; height: 31px; } .yfncnhltt img { border: 0; } .yfncnhltt img.video_play { position: absolute; bottom: 2px; left: 2px; width: 13px; height: 14px; } #yfiunv table td, #yfiadvdec table td { width: 1%; } #yfiunv table td.name, #yfiadvdec table th.first, #yfiadvdec table td.first { width: 10%; white-space: normal; } #leftcol{display:none;} #rightcol{display:block;} ...Click here to read the whole Article (external link)
Conceptus® to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Conceptus, Inc. (Nasdaq: CPTS - News), Essure®th Annual Healthcare Conference on Tuesday, November 17, 2009, at 2:10 p.m. ET. The conference will be held at the St. Regis Hotel in New York City. A live webcast of the presentation will be available by going to www.conceptus.com and clicking on the link to Live Webcasts. An archived replay will be available for a period of 30 days.About the Essure® ProcedureEssure® procedure is a permanent birth control method that can be done in the comfort of a physician’s office in about 13 minutes (average hysteroscopic procedure time) without hormones, cutting, burning or the risks associated with general anesthesia or tubal ligation. Small, flexible micro-inserts are placed in the woman’s fallopian tubes through the cervix without incisions. Over the next three months, the body forms a natural barrier around the micro-inserts to prevent sperm from reaching the egg. Essure is 99.8 percent effective (based on four...Click here to read the whole Article (external link)
CONCEPTUS INC Files SEC form 10-Q, Quarterly Report
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations The following discussion of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements and related notes thereto. This discussion contains forward-looking statements, including references to 2009 revenues and gross margins, increased product adoption, product improvements, expanded sales force and other forecasted items that involve risks and uncertainties such as our limited operating and sales history; the uncertainty of market acceptance of our product; dependence on obtaining and maintaining reimbursement; effectiveness and safety of our product over the long-term; our ability to obtain and maintain the necessary governmental clearances or approvals to market our product; our ability to develop and maintain proprietary aspects of our technology; our ability to manage our expansion; our dependence on single source suppliers, third party manufacturers and co-marketers; intense competition in the medical device industry and in the contraception market; the impact of a new competitor in the hysteroscopic sterilization segment; the inherent risk of exposure to product liability claims and product recalls and other factors referenced in this Form 10-Q. Our actual results could differ materially from those expressed or implied in these forward-looking statements as a result of various factors, including those discussed in our Annual Report on Form 10-K for the year ended December 31, 2008 filed with the Securities and Exchange Commission on March 13, 2009 and those included elsewhere in this Form 10-Q. Overview We develop, manufacture and market the Essure® permanent birth control system, an innovative, highly effective and proprietary medical device for women that was approved for marketing in the United States in November 2002 by the U.S. Food and Drug Administration, or FDA. The Essure system uses...Click here to read the whole Article (external link)
Conceptus® to Continue Patent Infringement Suit against Adiana® Permanent Contraception System
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Conceptus, Inc. (Nasdaq: CPTS - News), Essure® procedure, the first proven non-incisional permanent birth control method available, today announced that the United Stated District Court, Northern District of California has denied Conceptus’ motion for a preliminary injunction prohibiting Hologic, Inc. (Nasdaq: HOLX - News) from importing, using, selling or offering to sell the Adiana system in the United States. In May 2009 Conceptus filed suit against Hologic, asserting that the Adiana permanent contraception system infringes several U.S. patents owned by Conceptus. The Adiana permanent contraception system was approved by the U.S. Food and Drug Administration (FDA) in July 2009 and Conceptus filed its motion for a preliminary injunction shortly thereafter.“While we realized from the start that preliminary injunctions are rarely granted, we nonetheless are disappointed with the court’s decision on this matter. We continue to believe that at trial we will win on the merits of our case and prove conclusively that the Adiana s...Click here to read the whole Article (external link)
Conceptus® to Present at the Piper Jaffray 21st Annual Healthcare Conference
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Conceptus, Inc. (Nasdaq: CPTS - News), Essure®st Annual Healthcare Conference on Tuesday December 1, 2009, at 2:00 p.m. ET. The conference will be held at the New York Palace Hotel. A live webcast of the presentation will be available by going to www.conceptus.com and clicking on the link to Live Webcasts. An archived replay will be available for a period of 30 days.Essure® ProcedureEssure Essure based on four years of follow up with zero pregnancies reported in clinical trials, making it the most effective form of permanent birth control on the market. The procedure is covered by most insurance plans, and when it is performed in a doctor’s office the cost may be as low as a simple co-pay.EssureEssure Essure EssureEssure procedure.Essure® are registered trademarks of Conceptus Inc.About Conceptus, Inc.Conceptus, Inc. (NASDAQ: ...Click here to read the whole Article (external link)